Cargando…
Drug Repurposing of Metabolic Agents in Malignant Glioma
Gliomas are highly invasive brain tumors with short patient survival. One major pathogenic factor is aberrant tumor metabolism, which may be targeted with different specific and unspecific agents. Drug repurposing is of increasing interest in glioma research. Drugs interfering with the patient’s met...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164672/ https://www.ncbi.nlm.nih.gov/pubmed/30223473 http://dx.doi.org/10.3390/ijms19092768 |
_version_ | 1783359656539717632 |
---|---|
author | Seliger, Corinna Hau, Peter |
author_facet | Seliger, Corinna Hau, Peter |
author_sort | Seliger, Corinna |
collection | PubMed |
description | Gliomas are highly invasive brain tumors with short patient survival. One major pathogenic factor is aberrant tumor metabolism, which may be targeted with different specific and unspecific agents. Drug repurposing is of increasing interest in glioma research. Drugs interfering with the patient’s metabolism may also influence glioma metabolism. In this review, we outline definitions and methods for drug repurposing. Furthermore, we give insights into important candidates for a metabolic drug repurposing, namely metformin, statins, non-steroidal anti-inflammatory drugs, disulfiram and lonidamine. Advantages and pitfalls of drug repurposing will finally be discussed. |
format | Online Article Text |
id | pubmed-6164672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61646722018-10-10 Drug Repurposing of Metabolic Agents in Malignant Glioma Seliger, Corinna Hau, Peter Int J Mol Sci Review Gliomas are highly invasive brain tumors with short patient survival. One major pathogenic factor is aberrant tumor metabolism, which may be targeted with different specific and unspecific agents. Drug repurposing is of increasing interest in glioma research. Drugs interfering with the patient’s metabolism may also influence glioma metabolism. In this review, we outline definitions and methods for drug repurposing. Furthermore, we give insights into important candidates for a metabolic drug repurposing, namely metformin, statins, non-steroidal anti-inflammatory drugs, disulfiram and lonidamine. Advantages and pitfalls of drug repurposing will finally be discussed. MDPI 2018-09-14 /pmc/articles/PMC6164672/ /pubmed/30223473 http://dx.doi.org/10.3390/ijms19092768 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Seliger, Corinna Hau, Peter Drug Repurposing of Metabolic Agents in Malignant Glioma |
title | Drug Repurposing of Metabolic Agents in Malignant Glioma |
title_full | Drug Repurposing of Metabolic Agents in Malignant Glioma |
title_fullStr | Drug Repurposing of Metabolic Agents in Malignant Glioma |
title_full_unstemmed | Drug Repurposing of Metabolic Agents in Malignant Glioma |
title_short | Drug Repurposing of Metabolic Agents in Malignant Glioma |
title_sort | drug repurposing of metabolic agents in malignant glioma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164672/ https://www.ncbi.nlm.nih.gov/pubmed/30223473 http://dx.doi.org/10.3390/ijms19092768 |
work_keys_str_mv | AT seligercorinna drugrepurposingofmetabolicagentsinmalignantglioma AT haupeter drugrepurposingofmetabolicagentsinmalignantglioma |